Loading company
Heron Therapeutics, Inc.
HRTX · Nasdaq · ·
Next earnings: November 3, 2026
$0.31+5.0%Sep 29 close
- 1M
- -5.5%
- 6M
- -58.6%
- 1Y
- -75.5%
- 5Y
- -97.5%
HRTX · Nasdaq · ·
Next earnings: November 3, 2026
$0.31+5.0%Sep 29 close
Heron Therapeutics, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $37.7M | $37.2M | +1.25% |
| Profit | -$5.5M | -$2.4M | -130.53% |
| Profit per share | -$0.03 | -$0.02 | -50.00% |
| Free Cash Flow | -$2.4M | -$11.1M | +78.77% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Second quarter revenue grew compared to the first quarter but came in below our expectations,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Heron Therapeutics, Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Heron Therapeutics, Inc. has no earnings call transcript available.